Mirikizumab pharmacokinetics and exposure-response relationships in patients with moderately to severely active ulcerative colitis: results from randomised phase 2 and phase 3 induction and maintenance trials

被引：0
|
作者：
Friedrich, S. [1 ]
Chua, L. [1 ]
Zhang, X. C. [1 ]
机构：
[1] Eli Lilly & Co, Immunol, Indianapolis, IN USA
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P519
引用
收藏
页码：646 / 646
页数：1
相关论文
共 50 条
  • [41] Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND Study
    Louis, E.
    Panaccione, R.
    Parkes, G.
    Peyrin-Biroulet, L.
    Ferrante, M.
    Hisamatsu, T.
    Siegmund, B.
    Kalabic, J.
    Levine, P.
    Neimark, E.
    Wallace, K.
    Chen, S.
    Cheng, L.
    Duan, W. R.
    Armuzzi, A.
    Biederman, L.
    Loftus, E.
    Melmed, G.
    Schreiber, S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I10 - I12
  • [42] Cumulative Response to Guselkumab Through Week 24 of Induction in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study
    Rubin, David T.
    Sands, Bruce E.
    Lichtenstein, Gary R.
    Baker, Thomas
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Miao, Ye
    Zhang, Hongyan
    Nancey, Stephane
    Allegretti, Jessica R.
    Feagan, Brian G.
    Hisamatsu, Tadakazu
    Panes, Julian
    Dignass, Axel
    Bressler, Brian
    Peyrin-Biroulet, Laurent
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S672 - S673
  • [43] Cumulative response to guselkumab through week 24 of induction in patients with moderately to severely active ulcerative colitis: Results from the phase 3 QUASAR induction study
    Rubin, D.
    Sands, B.
    Lichtenstein, G.
    Baker, T.
    Huang, K. H.
    Germinaro, M.
    Miao, Y.
    Zhang, H.
    Nancey, S.
    Allegretti, J.
    Feagan, B.
    Hisamatsu, T.
    Panes, J.
    Dignass, A.
    Bressler, B.
    Peyrin-Biroulet, L.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1722 - I1723
  • [44] Mirikizumab pharmacokinetics and exposure-response in pediatric patients with moderate-to-severe ulcerative colitis
    Otani, Yuki
    Chua, Laiyi
    Komocsar, Wendy J.
    Larkin, Amy
    Johns, Jordan
    Zhang, Xin
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2025, 14 (03): : 474 - 485
  • [45] THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
    Allegretti, Jessica R.
    Peyrin-Biroulet, Laurent
    Feagan, Brian G.
    Bressler, Brian
    Lichtenstein, Gary R.
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Shipitofsky, Nicole
    Jiang, Lingjing
    Zhang, Hongyan
    Hisamatsu, Tadakazu
    Panes, Julian
    Dignass, Axel
    Sands, Bruce E.
    Rubin, David T.
    GASTROENTEROLOGY, 2023, 164 (06) : S1572 - S1572
  • [46] Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials (vol 399, pg 2113, 2022)
    Danese, S.
    Vermeire, S.
    Zhou, W.
    LANCET, 2022, 400 (10357): : 996 - 996
  • [47] Extended induction response over time in patients with moderately-to-severely active Ulcerative Colitis treated with mirikizumab in the LUCENT-1 and-2 trials
    Rubin, D. T.
    Charabaty, A.
    Jairath, V.
    Walter, J.
    McGinnis, K.
    Moses, R.
    Maier, S.
    Escobar, R.
    Baygani, S.
    Zaremba-Pechmann, L.
    Kobayashi, T.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1641 - I1642
  • [48] Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials
    Rubin, David T.
    Dotan, Iris
    DuVall, Aaron
    Bouhnik, Yoram
    Radford-Smith, Graham
    Higgins, Peter D. R.
    Mishkin, Daniel S.
    Arrisi, Pablo
    Scalori, Astrid
    Oh, Young S.
    Tole, Swati
    Chai, Akiko
    Chamberlain-James, Kirsten
    Lacey, Stuart
    McBride, Jacqueline
    Panes, Julian
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (01): : 17 - 27
  • [49] Pharmacokinetics and exposure-response analyses of upadacitinib in patients with moderate to severe ulcerative colitis - Analyses of induction and maintenance clinical trials
    Ponce-Bobadilla, A. V.
    Stodtmann, S.
    Eckert, D.
    Zhou, W.
    Liu, W.
    Mohamed, M. E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I355 - I357
  • [50] Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
    Rubin, David T.
    Allegretti, Jessica R.
    Panes, Julian
    Shipitofsky, Nicole
    Yarandi, Shadi S.
    Huang, Kuan-Hsiang Gary
    Germinaro, Matthew
    Wilson, Rebbecca
    Zhang, Hongyan
    Johanns, Jewel
    Feagan, Brian G.
    Hisamatsu, Tadakazu
    Lichtenstein, Gary R.
    Bressler, Brian
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    QUASAR Study Grp
    LANCET, 2025, 405 (10472): : 33 - 49
12345